DK3070091T3 - Benzodioxolderivater som phosphodiesterasehæmmere - Google Patents

Benzodioxolderivater som phosphodiesterasehæmmere Download PDF

Info

Publication number
DK3070091T3
DK3070091T3 DK16020112.5T DK16020112T DK3070091T3 DK 3070091 T3 DK3070091 T3 DK 3070091T3 DK 16020112 T DK16020112 T DK 16020112T DK 3070091 T3 DK3070091 T3 DK 3070091T3
Authority
DK
Denmark
Prior art keywords
phosphodyesterase
benzodioxoler
derivatives
benzodioxoler derivatives
Prior art date
Application number
DK16020112.5T
Other languages
English (en)
Inventor
Simon Feldbæk Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of DK3070091T3 publication Critical patent/DK3070091T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
DK16020112.5T 2010-06-24 2011-06-24 Benzodioxolderivater som phosphodiesterasehæmmere DK3070091T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
EP11729889.3A EP2585469B1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
DK3070091T3 true DK3070091T3 (da) 2019-07-08

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11729889.3T DK2585469T3 (da) 2010-06-24 2011-06-24 Heterocykliske benzodioxol- eller benzodioxepinforbindelser som phosphodiesterasehæmmere
DK16020112.5T DK3070091T3 (da) 2010-06-24 2011-06-24 Benzodioxolderivater som phosphodiesterasehæmmere

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11729889.3T DK2585469T3 (da) 2010-06-24 2011-06-24 Heterocykliske benzodioxol- eller benzodioxepinforbindelser som phosphodiesterasehæmmere

Country Status (29)

Country Link
US (3) US8980905B2 (da)
EP (2) EP2585469B1 (da)
JP (2) JP6174997B2 (da)
KR (1) KR101864578B1 (da)
CN (1) CN102958937B (da)
AU (1) AU2011269429B2 (da)
BR (1) BR112012032813B1 (da)
CA (1) CA2802895C (da)
CY (2) CY1117862T1 (da)
DK (2) DK2585469T3 (da)
ES (2) ES2733092T3 (da)
HR (2) HRP20160919T1 (da)
HU (2) HUE030081T2 (da)
IL (1) IL223329A (da)
LT (2) LT3070091T (da)
MX (1) MX2012014131A (da)
MY (1) MY157481A (da)
NZ (1) NZ603895A (da)
PL (2) PL3070091T3 (da)
PT (2) PT2585469T (da)
RS (2) RS58945B1 (da)
RU (1) RU2583787C2 (da)
SG (1) SG186140A1 (da)
SI (2) SI3070091T1 (da)
TR (1) TR201909709T4 (da)
TW (1) TWI507410B (da)
UA (1) UA109140C2 (da)
WO (1) WO2011160632A1 (da)
ZA (1) ZA201209031B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
MX2016016378A (es) 2014-06-23 2017-10-16 Leo Pharma As Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
DK3390407T3 (da) * 2015-12-18 2023-11-06 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
DK3642210T3 (da) * 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
PL3911304T3 (pl) 2019-01-15 2023-12-04 UNION therapeutics A/S Preparat w postaci tabletek o zmodyfikowanym uwalnianiu, zawierający inhibitory fosfodiesterazy
WO2021016409A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
KR20230159485A (ko) 2021-03-22 2023-11-21 유니온 테라퓨틱스 에이/에스 오리스밀라스트를 사용한 화농땀샘염의 치료
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
ATE325110T1 (de) 1995-05-19 2006-06-15 Kyowa Hakko Kogyo Kk Sauerstoff enthaltende heterocyclische verbindungen
CN1219171A (zh) * 1996-05-20 1999-06-09 达尔文发现有限公司 苯并呋喃甲酰胺及其治疗用途
WO1998022455A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AP2334A (en) * 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
UA98639C2 (en) * 2007-02-28 2012-06-11 Лео Фарма А/С Phosphodiesterase inhibitors
CA2676933C (en) * 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
PL2794603T3 (pl) * 2011-12-21 2017-08-31 Leo Pharma A/S [1,2,4]triazolopirydyny i ich zastosowanie jako inhibitory fosfodiesterazy

Also Published As

Publication number Publication date
ES2733092T3 (es) 2019-11-27
JP6174997B2 (ja) 2017-08-02
CA2802895C (en) 2019-05-21
RU2013103079A (ru) 2014-07-27
AU2011269429B2 (en) 2015-07-09
HUE044301T2 (hu) 2019-10-28
PT3070091T (pt) 2019-07-22
KR20130038341A (ko) 2013-04-17
TWI507410B (zh) 2015-11-11
SI2585469T1 (sl) 2016-11-30
IL223329A (en) 2017-01-31
US9273064B2 (en) 2016-03-01
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
PT2585469T (pt) 2016-08-29
HK1182699A1 (zh) 2013-12-06
CA2802895A1 (en) 2011-12-29
PL2585469T3 (pl) 2017-07-31
CY1122201T1 (el) 2020-11-25
MX2012014131A (es) 2013-01-29
US8980905B2 (en) 2015-03-17
EP2585469A1 (en) 2013-05-01
WO2011160632A1 (en) 2011-12-29
EP3070091A1 (en) 2016-09-21
EP2585469B1 (en) 2016-05-25
LT2585469T (lt) 2016-10-10
PL3070091T3 (pl) 2019-09-30
ES2584055T3 (es) 2016-09-23
JP2013529602A (ja) 2013-07-22
US20130123291A1 (en) 2013-05-16
CY1117862T1 (el) 2017-05-17
CN102958937B (zh) 2016-03-30
NZ603895A (en) 2014-10-31
SI3070091T1 (sl) 2019-08-30
BR112012032813B1 (pt) 2022-02-01
HUE030081T2 (en) 2017-04-28
HRP20160919T1 (hr) 2016-10-07
TR201909709T4 (tr) 2019-07-22
UA109140C2 (uk) 2015-07-27
RS58945B1 (sr) 2019-08-30
US9637499B2 (en) 2017-05-02
LT3070091T (lt) 2019-07-25
SG186140A1 (en) 2013-01-30
RU2583787C2 (ru) 2016-05-10
DK2585469T3 (da) 2016-08-29
BR112012032813A2 (pt) 2016-11-08
US20160022657A1 (en) 2016-01-28
ZA201209031B (en) 2014-02-26
IL223329A0 (en) 2013-02-03
RS55104B1 (sr) 2016-12-30
HRP20191136T1 (hr) 2019-09-20
MY157481A (en) 2016-06-15
KR101864578B1 (ko) 2018-06-07
US20150111915A1 (en) 2015-04-23
EP3070091B1 (en) 2019-04-17
JP2016164168A (ja) 2016-09-08
TW201206940A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
EP2563129A4 (en) N3-SUBSTITUTED N1-SULFONYL-5-FLUORPYRIMIDINONE DERIVATIVES
PT2684880T (pt) Derivado de dispiropirrolidina
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
DK3070091T3 (da) Benzodioxolderivater som phosphodiesterasehæmmere
DK3124483T3 (da) Pyrazolaminopyrimidin-derivater som LRRK2-modulatorer
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
PL2614063T3 (pl) Podstawione imidazopirydazyny
DK3225404T3 (da) Fluidpatron
EP2578585A4 (en) Purinone derivative
BR112012028556A2 (pt) Indóis
DK2616465T3 (da) Triazin-oxadiazoler
DE10170954T8 (de) Mikrowellendruckgarer
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011102080A5 (de) Kupplungszentralausrücker
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
EP2646037A4 (en) INHIBITION OF HISTONES
DK2448659T3 (da) Rotorskive
CO6960557A2 (es) Derivados de 2-yodo-imidazol
EP2571003A4 (en) RISK CALCULATION APPARATUS
DE112011102711A5 (de) Hydrostataktor